# GILD catalysts: GILEAD SCIENCES, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/gild/catalysts

> GILEAD SCIENCES, INC. (GILD) has 70 upcoming catalysts. The next is the sacituzumab govitecan-hziy primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | GILEAD SCIENCES, INC. |
| Ticker | GILD (Nasdaq) |
| SEC CIK | 882095 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/gild |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 1, 2016 | [Odefsey (emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate) FDA approval](https://sec-api.dev/pdufa/emtricitabine-rilpivirine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA208351 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20160301, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product ODEFSEY (EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208351%22)) |
| April 4, 2016 | [Descovy (emtricitabine; tenofovir alafenamide fumarate) FDA approval](https://sec-api.dev/pdufa/emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA208215 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20160404, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product DESCOVY (EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208215%22)) |
| June 28, 2016 | [Epclusa (sofosbuvir; velpatasvir) FDA approval](https://sec-api.dev/pdufa/sofosbuvir-velpatasvir) | GILD |  | completed, approved | "NDA208341 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20160628, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208341%22)) |
| November 10, 2016 | [Vemlidy (tenofovir alafenamide fumarate) FDA approval](https://sec-api.dev/pdufa/tenofovir-alafenamide) | GILD |  | completed, approved | "NDA208464 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20161110, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22)) |
| July 18, 2017 | [Vosevi (sofosbuvir; velpatasvir; voxilaprevir) FDA approval](https://sec-api.dev/pdufa/sofosbuvir-velpatasvir-voxilaprevir) | GILD |  | completed, approved | "NDA209195 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20170718, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product VOSEVI (SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209195%22)) |
| February 7, 2018 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) FDA approval](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA210251 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20180207, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22)) |
| August 28, 2019 | [Harvoni (ledipasvir; sofosbuvir) FDA approval](https://sec-api.dev/pdufa/ledipasvir-sofosbuvir) | GILD |  | completed, approved | "NDA212477 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20190828, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product HARVONI (LEDIPASVIR; SOFOSBUVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212477%22)) |
| August 28, 2019 | [Sovaldi® (sofosbuvir) FDA approval](https://sec-api.dev/pdufa/sofosbuvir) | GILD |  | completed, approved | "NDA212480 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20190828, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product SOVALDI (SOFOSBUVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212480%22)) |
| February 4, 2020 | [Vemlidy (tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/tenofovir-alafenamide) | GILD |  | completed, approved | "NDA208464 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20200204, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22)) |
| March 19, 2020 | [Epclusa (sofosbuvir; velpatasvir) label expansion decision](https://sec-api.dev/pdufa/sofosbuvir-velpatasvir) | GILD |  | completed, approved | "NDA208341 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20200319, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208341%22)) |
| July 14, 2020 | [Epclusa (sofosbuvir; velpatasvir) label expansion decision](https://sec-api.dev/pdufa/sofosbuvir-velpatasvir) | GILD |  | completed, approved | "NDA208341 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20200714, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208341%22)) |
| August 18, 2020 | [Vemlidy (tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/tenofovir-alafenamide) | GILD |  | completed, approved | "NDA208464 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20200818, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22)) |
| October 22, 2020 | [Veklury (remdesivir) FDA approval](https://sec-api.dev/pdufa/remdesivir) | GILD |  | completed, approved | "NDA214787 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20201022, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product VEKLURY (REMDESIVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214787%22)) |
| February 5, 2021 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA210251 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20210205, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22)) |
| February 24, 2021 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA210251 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20210224, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22)) |
| June 10, 2021 | [Epclusa (sofosbuvir; velpatasvir) FDA approval](https://sec-api.dev/pdufa/sofosbuvir-velpatasvir) | GILD |  | completed, approved | "NDA214187 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20210610, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214187%22)) |
| June 10, 2021 | [Epclusa (sofosbuvir; velpatasvir) label expansion decision](https://sec-api.dev/pdufa/sofosbuvir-velpatasvir) | GILD |  | completed, approved | "NDA208341 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20210610, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208341%22)) |
| October 7, 2021 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA210251 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20211007, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22)) |
| January 7, 2022 | [Genvoya (cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/cobicistat-elvitegravir-emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA207561 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20220107, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product GENVOYA (COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207561%22)) |
| January 7, 2022 | [Descovy (emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA208215 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20220107, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product DESCOVY (EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208215%22)) |
| January 21, 2022 | [Veklury (remdesivir) label expansion decision](https://sec-api.dev/pdufa/remdesivir) | GILD |  | completed, approved | "NDA214787 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20220121, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product VEKLURY (REMDESIVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214787%22)) |
| February 28, 2022 | [Yeztugo® (lenacapavir) complete response letter (CRL)](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22215973%2C215974Orig1s000OtherActionLtrs.pdf%22)) |
| April 25, 2022 | [Veklury (remdesivir) label expansion decision](https://sec-api.dev/pdufa/remdesivir) | GILD |  | completed, approved | "NDA214787 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20220425, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product VEKLURY (REMDESIVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214787%22)) |
| April 27, 2022 | [Epclusa (sofosbuvir; velpatasvir) label expansion decision](https://sec-api.dev/pdufa/sofosbuvir-velpatasvir) | GILD |  | completed, approved | "NDA208341 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20220427, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product EPCLUSA (SOFOSBUVIR; VELPATASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208341%22)) |
| Oct 2022 | [Hepcludex® (bulevirtide) complete response letter (CRL)](https://sec-api.dev/pdufa/bulevirtide) | GILD | with hepatitis delta virus infection | completed, complete response letter | "For example, in October 2022, we announced that FDA issued a complete response letter for our Biologics License Application for bulevirtide for the treatment of adults with hepatitis delta virus infection." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/gild-20250331.htm)) |
| October 14, 2022 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA210251 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20221014, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22)) |
| October 17, 2022 | [Vemlidy (tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/tenofovir-alafenamide) | GILD |  | completed, approved | "NDA208464 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20221017, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22)) |
| December 22, 2022 | [Yeztugo® (lenacapavir) FDA approval](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed, approved | "Sunlenca \| lenacapavir \| 12/22/2022 \| To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerationsPress Release (FDA Archive)Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| July 13, 2023 | [Veklury (remdesivir) label expansion decision](https://sec-api.dev/pdufa/remdesivir) | GILD |  | completed, approved | "NDA214787 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20230713, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product VEKLURY (REMDESIVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214787%22)) |
| February 23, 2024 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA210251 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20240223, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22)) |
| February 28, 2024 | [Veklury (remdesivir) label expansion decision](https://sec-api.dev/pdufa/remdesivir) | GILD |  | completed, approved | "NDA214787 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20240228, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product VEKLURY (REMDESIVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214787%22)) |
| March 27, 2024 | [Vemlidy (tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/tenofovir-alafenamide) | GILD |  | completed, approved | "NDA208464 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20240327, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208464%22)) |
| April 24, 2024 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA210251 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20240424, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22)) |
| August 14, 2024 | [Livdelzi® (seladelpar) FDA approval](https://sec-api.dev/pdufa/seladelpar) | GILD | To treat primary biliary cholangitis (PBC) | completed, approved | "Livdelzi \| seladelpar \| 8/14/2024 \| To treat primary biliary cholangitis (PBC)Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| November 25, 2024 | [Yeztugo® (lenacapavir) label expansion decision](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed, approved | "NDA215974 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20241125, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product SUNLENCA (LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215974%22)) |
| February 11, 2025 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000003/exhibit991earningspressrel.htm)) |
| February 19, 2025 | [Odefsey (emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/emtricitabine-rilpivirine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA208351 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20250219, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product ODEFSEY (EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208351%22)) |
| April 24, 2025 | [Yeztugo® (lenacapavir) NDA/BLA acceptance](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed | "•Announced FDA accepted New Drug Application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a PDUFA date of June 19, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm)) |
| April 24, 2025 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm)) |
| May 8, 2025 | [Obeldesivir primary completion](https://sec-api.dev/pdufa/obeldesivir) | GILD | RSV Infection | withdrawn | "NCT06585150 (Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585150)) |
| June 13, 2025 | [Tybost (cobicistat) primary completion](https://sec-api.dev/pdufa/cobicistat) | GILD | Acquired Immune Deficiency Syndrome (AIDS); HIV Infections | completed | "NCT02016924 (Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-06-13 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02016924)) |
| June 17, 2025 | [Fludarabine primary completion](https://sec-api.dev/pdufa/fludarabine) | GILD | Relapsed/Refractory Mantle Cell Lymphoma | completed | "NCT04880434 (Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04880434)) |
| June 18, 2025 | [Yeztugo® (lenacapavir) FDA approval](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed, approved | "NDA220020 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20250618, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product YEZTUGO (LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220020%22)) |
| June 18, 2025 | [Yeztugo (lenacapavir; lenacapavir sodium) FDA approval](https://sec-api.dev/pdufa/lenacapavir-lenacapavir) | GILD |  | completed, approved | "NDA220018 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20250618, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product YEZTUGO (LENACAPAVIR; LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220018%22)) |
| June 19, 2025 | [Yeztugo® (lenacapavir) PDUFA date](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed, approved | "•Announced FDA accepted New Drug Application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a PDUFA date of June 19, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm)) |
| June 20, 2025 | [Tybost (cobicistat) label expansion decision](https://sec-api.dev/pdufa/cobicistat) | GILD |  | completed, approved | "NDA203094 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20250620, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product TYBOST (COBICISTAT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203094%22)) |
| June 20, 2025 | [Descovy (emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA208215 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20250620, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product DESCOVY (EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208215%22)) |
| 2H 2025 | [Yeztugo® (lenacapavir) trial start](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | scheduled | "•Presented initial Phase 1 data evaluating investigational once-yearly lenacapavir for HIV prevention at the Conference on Retroviruses and Opportunistic Infections ("CROI"), and announced plans to launch a Phase 3 study in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm)) |
| July 4, 2025 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Locally Advanced or Metastatic Unresectable Urothelial Cancer | completed | "NCT04527991 (Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-04 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-06-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04527991)) |
| July 30, 2025 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) label expansion decision](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD |  | completed, approved | "NDA210251 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20250730, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIKTARVY (BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210251%22)) |
| August 7, 2025 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000030/exhibit991earningspressrel.htm)) |
| September 29, 2025 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT05502341 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-09-29 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05502341)) |
| October 27, 2025 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT06333808 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-11-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06333808)) |
| October 30, 2025 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000044/exhibit991earningspressrel.htm)) |
| November 24, 2025 | [Yescarta (axicabtagene ciloleucel) primary completion](https://sec-api.dev/pdufa/axicabtagene-ciloleucel) | GILD | Relapsed or Refractory Large B-cell Lymphoma | completed | "NCT05459571 (Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-24 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05459571)) |
| December 17, 2025 | [Edecesertib primary completion](https://sec-api.dev/pdufa/edecesertib) | GILD | Cutaneous Lupus Erythematosus (CLE) | withdrawn | "NCT05629208 (Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-12-17 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05629208)) |
| February 10, 2026 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000003/exhibit991earningspressrel.htm)) |
| March 4, 2026 | [Emvistegrast primary completion](https://sec-api.dev/pdufa/emvistegrast) | GILD | Ulcerative Colitis | completed | "NCT06290934 (Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06290934)) |
| March 16, 2026 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) primary completion](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD | HIV-1-infection | withdrawn | "NCT06613685 (Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2026-03-16 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06613685)) |
| April 17, 2026 | [Isl/len primary completion](https://sec-api.dev/pdufa/isl-len) | GILD | HIV-1-infection | completed | "NCT06630286 (Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-17 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06630286)) |
| April 23, 2026 | [Isl/len primary completion](https://sec-api.dev/pdufa/isl-len) | GILD | HIV-1-Infection | completed | "NCT06630299 (Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-23 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06630299)) |
| May 6, 2026 | [Livdelzi® (seladelpar) primary completion](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cholangitis | completed | "NCT06060665 (Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-06 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06060665)) |
| May 7, 2026 | [Bictegravir NDA/BLA acceptance](https://sec-api.dev/pdufa/bictegravir) | GILD |  | completed | "•Announced U.S. Food and Drug Administration ("FDA") accepted New Drug Application for bictegravir and lenacapavir ("BIC/LEN") for virologically suppressed people with HIV under priority review, with a Prescription Drug User Fee Act ("PDUFA") target action date of August 27, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm)) |
| May 7, 2026 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES FIRST QUARTER FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm)) |
| May 7, 2026 | [Anitocabtagene autoleucel NDA/BLA acceptance](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD |  | completed | "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm)) |
| May 22, 2026 | [Hepcludex (bulevirtide-gmod) FDA approval](https://sec-api.dev/pdufa/bulevirtide-gmod) | GILD |  | completed, approved | "Hepcludex \| bulevirtide-gmod \| 5/22/2026 \| To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| May 28, 2026 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | Pre-Exposure Prophylaxis of HIV Infection | completed | "NCT06513312 (Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06513312)) |
| June 2, 2026 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Locally Advanced or Metastatic Unresectable Urothelial Cancer | completed | "NCT04527991 (Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-04 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-06-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04527991?tab=results)) |
| July 22, 2026 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | Pre-Exposure Prophylaxis of HIV Infection | completed | "NCT06101329 (Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-22 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06101329)) |
| July 27, 2026 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | Pre-Exposure Prophylaxis of HIV Infection | completed | "NCT06101342 (Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-27 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06101342)) |
| August 4, 2026 | [Yeztugo® (lenacapavir) NDA/BLA acceptance](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed | "•Announced U.S. Food and Drug Administration ("FDA") accepted a supplemental New Drug Application submission for Yeztugo® (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis ("PrEP"), with a Prescription Drug User Fee Act target action date of February 2, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm)) |
| August 4, 2026 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm)) |
| August 18, 2026 | [Fludarabine topline data readout](https://sec-api.dev/pdufa/fludarabine) | GILD | Relapsed/Refractory Mantle Cell Lymphoma | completed | "NCT04880434 (Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04880434?tab=results)) |
| August 27, 2026 | [Bixlenvo (bictegravir sodium; lenacapavir sodium) FDA approval](https://sec-api.dev/pdufa/bictegravir-lenacapavir) | GILD |  | completed, approved | "NDA221104 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20260827, review_priority PRIORITY; sponsor_name GILEAD SCIENCES INC; product BIXLENVO (BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA221104%22)) |
| August 27, 2026 | [Bixlenvo Sunlenca Starter Pack (Copackaged) (bictegravir sodium, lenacapavir sodium; lenacapavir sodium) FDA approval](https://sec-api.dev/pdufa/bictegravir-lenacapavir-lenacapavir) | GILD |  | completed, approved | "NDA221443 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20260827, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product BIXLENVO SUNLENCA STARTER PACK (COPACKAGED) (BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA221443%22)) |
| August 27, 2026 | [Bictegravir PDUFA date](https://sec-api.dev/pdufa/bictegravir) | GILD |  | scheduled | "•Announced U.S. Food and Drug Administration ("FDA") accepted New Drug Application for bictegravir and lenacapavir ("BIC/LEN") for virologically suppressed people with HIV under priority review, with a Prescription Drug User Fee Act ("PDUFA") target action date of August 27, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm)) |
| August 27, 2026 | [Yeztugo® (lenacapavir) label expansion decision](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed, approved | "NDA215974 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20260827, review_priority STANDARD; sponsor_name GILEAD SCIENCES INC; product SUNLENCA (LENACAPAVIR SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215974%22)) |
| October 2026 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Solid Tumor | delayed | "NCT05119907 (Study of Sacituzumab Govitecan in Patients With Solid Tumor): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05119907)) |
| Oct 2026 to Jan 2027 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Solid Tumor | scheduled | "NCT05119907 (Study of Sacituzumab Govitecan in Patients With Solid Tumor): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05119907)) |
| October 21, 2026 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT05502341 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-09-29 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05502341?tab=results)) |
| October 27, 2026 | [Taf primary completion](https://sec-api.dev/pdufa/taf) | GILD | Chronic Hepatitis B | completed | "NCT02932150 (Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02932150)) |
| Oct 2026 to Jan 2027 | [Taf topline data readout](https://sec-api.dev/pdufa/taf) | GILD | Chronic Hepatitis B | scheduled | "NCT02932150 (Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-27 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02932150)) |
| October 29, 2026 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000037/exhibit991earningspressrel.htm)) |
| November 5, 2026 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT06333808 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-11-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06333808?tab=results)) |
| November 12, 2026 | [Yescarta (axicabtagene ciloleucel) topline data readout](https://sec-api.dev/pdufa/axicabtagene-ciloleucel) | GILD | Relapsed or Refractory Large B-cell Lymphoma | completed | "NCT05459571 (Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-24 (ACTUAL); Lead Sponsor Kite, A Gilead Company; Results First Posted 2026-11-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05459571?tab=results)) |
| December 2026 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Metastatic Breast Cancer | scheduled | "NCT04639986 (Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04639986)) |
| Dec 2026 to Mar 2027 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Metastatic Breast Cancer | scheduled | "NCT04639986 (Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04639986)) |
| December 2026 | [Anitocabtagene autoleucel primary completion](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | Multiple Myeloma | scheduled | "NCT05396885 (Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05396885)) |
| Dec 2026 to Mar 2027 | [Anitocabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | Multiple Myeloma | scheduled | "NCT05396885 (Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05396885)) |
| December 23, 2026 | [Anitocabtagene autoleucel PDUFA date](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | relapsed or refractory multiple myeloma | scheduled | "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm)) |
| January 2027 | [Tilpisertib fosmecarbil primary completion](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) | GILD | Ulcerative Colitis | scheduled | "NCT06029972 (Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06029972)) |
| Jan to Apr 2027 | [Tilpisertib fosmecarbil topline data readout](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) | GILD | Ulcerative Colitis | scheduled | "NCT06029972 (Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06029972)) |
| February 2027 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Triple Negative Breast Cancer; PD-L1 Positive | scheduled | "NCT05382286 (Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05382286)) |
| Feb to May 2027 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Triple Negative Breast Cancer; PD-L1 Positive | scheduled | "NCT05382286 (Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05382286)) |
| February 2, 2027 | [Yeztugo® (lenacapavir) PDUFA date](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | scheduled | "•Announced U.S. Food and Drug Administration ("FDA") accepted a supplemental New Drug Application submission for Yeztugo® (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis ("PrEP"), with a Prescription Drug User Fee Act target action date of February 2, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/exhibit991earningspressrel.htm)) |
| March 2027 | [Sacituzumab govitecan-hziy (sg) primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) | GILD | Non-small Cell Lung Cancer | scheduled | "NCT05186974 (Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05186974)) |
| Mar to Jun 2027 | [Sacituzumab govitecan-hziy (sg) topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) | GILD | Non-small Cell Lung Cancer | scheduled | "NCT05186974 (Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05186974)) |
| March 2027 | [Domvanalimab primary completion](https://sec-api.dev/pdufa/domvanalimab) | GILD | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06727565 (Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06727565)) |
| Mar to Jun 2027 | [Domvanalimab topline data readout](https://sec-api.dev/pdufa/domvanalimab) | GILD | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06727565 (Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06727565)) |
| March 2027 | [Oral lenacapavir primary completion](https://sec-api.dev/pdufa/oral-lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT06749054 (Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06749054)) |
| Mar to Jun 2027 | [Oral lenacapavir topline data readout](https://sec-api.dev/pdufa/oral-lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT06749054 (Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06749054)) |
| June 2027 | [Sacituzumab govitecan-hziy (sg) primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) | GILD | Triple Negative Breast Cancer | scheduled | "NCT05633654 (Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05633654)) |
| Jun to Sep 2027 | [Sacituzumab govitecan-hziy (sg) topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) | GILD | Triple Negative Breast Cancer | scheduled | "NCT05633654 (Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05633654)) |
| July 2027 | [Kte-x19 primary completion](https://sec-api.dev/pdufa/kte-x19) | GILD |  | scheduled | "NCT06253663 (Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06253663)) |
| Jul to Oct 2027 | [Kte-x19 topline data readout](https://sec-api.dev/pdufa/kte-x19) | GILD |  | scheduled | "NCT06253663 (Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06253663)) |
| August 2027 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07645287 (A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07645287)) |
| Aug to Nov 2027 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07645287 (A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07645287)) |
| August 2027 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1 Infection | scheduled | "NCT07841990 (Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07841990)) |
| Aug to Nov 2027 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1 Infection | scheduled | "NCT07841990 (Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07841990)) |
| November 2027 | [GS-1179 primary completion](https://sec-api.dev/pdufa/gs-1179) | GILD | HSV-2 Infection | scheduled | "NCT07912996 (Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07912996)) |
| Nov 2027 to Feb 2028 | [GS-1179 topline data readout](https://sec-api.dev/pdufa/gs-1179) | GILD | HSV-2 Infection | scheduled | "NCT07912996 (Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07912996)) |
| December 2027 | [Domvanalimab primary completion](https://sec-api.dev/pdufa/domvanalimab) | GILD | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05676931 (Study With Various Immunotherapy Treatments in Participants With Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05676931)) |
| Dec 2027 to Mar 2028 | [Domvanalimab topline data readout](https://sec-api.dev/pdufa/domvanalimab) | GILD | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05676931 (Study With Various Immunotherapy Treatments in Participants With Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05676931)) |
| January 2028 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) primary completion](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD | HIV-1-Infection | scheduled | "NCT06544733 (Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544733)) |
| Jan to Apr 2028 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) topline data readout](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD | HIV-1-Infection | scheduled | "NCT06544733 (Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544733)) |
| April 2028 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer | scheduled | "NCT05840211 (Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05840211)) |
| Apr to Jul 2028 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer | scheduled | "NCT05840211 (Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05840211)) |
| June 2028 | [YuTuo (zimberelimab) primary completion](https://sec-api.dev/pdufa/zimberelimab) | GILD | Non-small Cell Lung Cancer | scheduled | "NCT05502237 (Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05502237)) |
| Jun to Sep 2028 | [YuTuo (zimberelimab) topline data readout](https://sec-api.dev/pdufa/zimberelimab) | GILD | Non-small Cell Lung Cancer | scheduled | "NCT05502237 (Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05502237)) |
| July 2028 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Triple Negative Breast Cancer; PD-L1 Negative | scheduled | "NCT05382299 (Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05382299)) |
| Jul to Oct 2028 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Triple Negative Breast Cancer; PD-L1 Negative | scheduled | "NCT05382299 (Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05382299)) |
| July 2028 | [Anitocabtagene autoleucel primary completion](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | Multiple Myeloma | scheduled | "NCT06413498 (A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06413498)) |
| Jul to Oct 2028 | [Anitocabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | Multiple Myeloma | scheduled | "NCT06413498 (A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06413498)) |
| September 2028 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV Pre-exposure Prophylaxis | scheduled | "NCT07047716 (Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07047716)) |
| Sep to Dec 2028 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV Pre-exposure Prophylaxis | scheduled | "NCT07047716 (Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07047716)) |
| November 2028 | [Livdelzi® (seladelpar) primary completion](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cirrhosis | scheduled | "NCT03301506 (Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03301506)) |
| Nov 2028 to Feb 2029 | [Livdelzi® (seladelpar) topline data readout](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cirrhosis | scheduled | "NCT03301506 (Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03301506)) |
| December 2028 | [Denikitug primary completion](https://sec-api.dev/pdufa/denikitug) | GILD | Advanced Microsatellite Stable Colorectal Cancer | scheduled | "NCT07527858 (Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07527858)) |
| Dec 2028 to Mar 2029 | [Denikitug topline data readout](https://sec-api.dev/pdufa/denikitug) | GILD | Advanced Microsatellite Stable Colorectal Cancer | scheduled | "NCT07527858 (Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07527858)) |
| December 2028 | [Livdelzi® (seladelpar) primary completion](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cholangitis | scheduled | "NCT07841977 (Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07841977)) |
| Dec 2028 to Mar 2029 | [Livdelzi® (seladelpar) topline data readout](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cholangitis | scheduled | "NCT07841977 (Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07841977)) |
| March 2029 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV Infections | scheduled | "NCT07682961 (Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07682961)) |
| Mar to Jun 2029 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV Infections | scheduled | "NCT07682961 (Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07682961)) |
| March 2029 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07683000 (Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07683000)) |
| Mar to Jun 2029 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07683000 (Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07683000)) |
| May 2029 | [TUB-040 primary completion](https://sec-api.dev/pdufa/tub-040) | GILD | NSCLC; Non Small Cell Lung Cancer | scheduled | "NCT07806773 (Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07806773)) |
| May to Aug 2029 | [TUB-040 topline data readout](https://sec-api.dev/pdufa/tub-040) | GILD | NSCLC; Non Small Cell Lung Cancer | scheduled | "NCT07806773 (Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07806773)) |
| June 2029 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Endometrial Cancer | scheduled | "NCT06486441 (Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06486441)) |
| Jun to Sep 2029 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Endometrial Cancer | scheduled | "NCT06486441 (Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06486441)) |
| September 2029 | [Zimberelimab (zim) primary completion](https://sec-api.dev/pdufa/zimberelimab-zim) | GILD |  | scheduled | "NCT05633667 (Study of Novel Treatment Combinations in Patients With Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05633667)) |
| Sep to Dec 2029 | [Zimberelimab (zim) topline data readout](https://sec-api.dev/pdufa/zimberelimab-zim) | GILD |  | scheduled | "NCT05633667 (Study of Novel Treatment Combinations in Patients With Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05633667)) |
| October 2029 | [Sacituzumab govitecan (sg) primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-sg) | GILD | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | scheduled | "NCT06801834 (Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06801834)) |
| Oct 2029 to Jan 2030 | [Sacituzumab govitecan (sg) topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-sg) | GILD | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | scheduled | "NCT06801834 (Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06801834)) |
| January 2030 | [Denikitug primary completion](https://sec-api.dev/pdufa/denikitug) | GILD | HER2-negative; Gastroesophageal Junction; Esophageal Adenocarcinoma | scheduled | "NCT07546812 (Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07546812)) |
| Jan to Apr 2030 | [Denikitug topline data readout](https://sec-api.dev/pdufa/denikitug) | GILD | HER2-negative; Gastroesophageal Junction; Esophageal Adenocarcinoma | scheduled | "NCT07546812 (Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07546812)) |
| April 2030 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Metastatic Urothelial Cancer | scheduled | "NCT03547973 (Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03547973)) |
| Apr to Jul 2030 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Metastatic Urothelial Cancer | scheduled | "NCT03547973 (Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03547973)) |
| July 2030 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT06532656 (Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-07 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06532656)) |
| Jul to Oct 2030 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT06532656 (Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-07 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06532656)) |
| August 2030 | [Livdelzi® (seladelpar) primary completion](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cholangitis | scheduled | "NCT06051617 (Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06051617)) |
| Aug to Nov 2030 | [Livdelzi® (seladelpar) topline data readout](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cholangitis | scheduled | "NCT06051617 (Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06051617)) |
| October 2030 | [Yescarta (axicabtagene ciloleucel) primary completion](https://sec-api.dev/pdufa/axicabtagene-ciloleucel) | GILD | Relapsed/Refractory Follicular Lymphoma | scheduled | "NCT05371093 (Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05371093)) |
| Oct 2030 to Jan 2031 | [Yescarta (axicabtagene ciloleucel) topline data readout](https://sec-api.dev/pdufa/axicabtagene-ciloleucel) | GILD | Relapsed/Refractory Follicular Lymphoma | scheduled | "NCT05371093 (Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05371093)) |
| October 2030 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07708727 (Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07708727)) |
| Oct 2030 to Jan 2031 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07708727 (Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07708727)) |

## Drugs

- [Anitocabtagene autoleucel](https://sec-api.dev/pdufa/anitocabtagene-autoleucel): relapsed or refractory multiple myeloma, Multiple Myeloma
- [Yescarta (axicabtagene ciloleucel)](https://sec-api.dev/pdufa/axicabtagene-ciloleucel): Relapsed or Refractory Large B-cell Lymphoma, Relapsed/Refractory Follicular Lymphoma
- [Bictegravir](https://sec-api.dev/pdufa/bictegravir): 
- [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide): HIV-1-Infection
- [Bixlenvo (bictegravir sodium; lenacapavir sodium)](https://sec-api.dev/pdufa/bictegravir-lenacapavir): 
- [Bixlenvo Sunlenca Starter Pack (Copackaged) (bictegravir sodium, lenacapavir sodium; lenacapavir sodium)](https://sec-api.dev/pdufa/bictegravir-lenacapavir-lenacapavir): 
- [Hepcludex® (bulevirtide)](https://sec-api.dev/pdufa/bulevirtide): with hepatitis delta virus infection
- [Hepcludex (bulevirtide-gmod)](https://sec-api.dev/pdufa/bulevirtide-gmod): 
- [Tybost (cobicistat)](https://sec-api.dev/pdufa/cobicistat): Acquired Immune Deficiency Syndrome (AIDS)
- [Genvoya (cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate)](https://sec-api.dev/pdufa/cobicistat-elvitegravir-emtricitabine-tenofovir-alafenamide): 
- [Denikitug](https://sec-api.dev/pdufa/denikitug): Advanced Microsatellite Stable Colorectal Cancer, HER2-negative
- [Edecesertib](https://sec-api.dev/pdufa/edecesertib): Cutaneous Lupus Erythematosus (CLE)
- [Odefsey (emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate)](https://sec-api.dev/pdufa/emtricitabine-rilpivirine-tenofovir-alafenamide): 
- [Descovy (emtricitabine; tenofovir alafenamide fumarate)](https://sec-api.dev/pdufa/emtricitabine-tenofovir-alafenamide): 
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast): Ulcerative Colitis
- [Fludarabine](https://sec-api.dev/pdufa/fludarabine): lupus, the initial dose cohort, Relapsed/Refractory Mantle Cell Lymphoma
- [GS-1179](https://sec-api.dev/pdufa/gs-1179): HSV-2 Infection
- [Isl/len](https://sec-api.dev/pdufa/isl-len): HIV-1-Infection
- [Kte-x19](https://sec-api.dev/pdufa/kte-x19): Relapsed/Refractory Mantle Cell Lymphoma
- [Harvoni (ledipasvir; sofosbuvir)](https://sec-api.dev/pdufa/ledipasvir-sofosbuvir): 
- [Yeztugo® (lenacapavir)](https://sec-api.dev/pdufa/lenacapavir): HIV-1-infection, Pre-Exposure Prophylaxis of HIV Infection, HIV-1 Infection, HIV Infections, HIV Pre-exposure Prophylaxis
- [Yeztugo (lenacapavir; lenacapavir sodium)](https://sec-api.dev/pdufa/lenacapavir-lenacapavir): 
- [Obeldesivir](https://sec-api.dev/pdufa/obeldesivir): RSV Infection
- [Oral lenacapavir](https://sec-api.dev/pdufa/oral-lenacapavir): HIV-1-infection
- [Veklury (remdesivir)](https://sec-api.dev/pdufa/remdesivir): 
- [Sacituzumab govitecan-hziy](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy): Locally Advanced or Metastatic Unresectable Urothelial Cancer, Metastatic Urothelial Cancer, Triple Negative Breast Cancer, Locally Advanced or Unresectable Metastatic Breast Cancer, Endometrial Cancer, Metastatic Breast Cancer, Solid Tumor
- [Sacituzumab govitecan-hziy (sg)](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg): Non-small Cell Lung Cancer, Triple Negative Breast Cancer
- [Sacituzumab govitecan (sg)](https://sec-api.dev/pdufa/sacituzumab-govitecan-sg): Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- [Livdelzi® (seladelpar)](https://sec-api.dev/pdufa/seladelpar): To treat primary biliary cholangitis (PBC), Primary Biliary Cholangitis, Primary Biliary Cirrhosis
- [Sovaldi® (sofosbuvir)](https://sec-api.dev/pdufa/sofosbuvir): population and achieving the trial's primary endpoint
- [Epclusa (sofosbuvir; velpatasvir)](https://sec-api.dev/pdufa/sofosbuvir-velpatasvir): 
- [Vosevi (sofosbuvir; velpatasvir; voxilaprevir)](https://sec-api.dev/pdufa/sofosbuvir-velpatasvir-voxilaprevir): 
- [Taf](https://sec-api.dev/pdufa/taf): Chronic Hepatitis B
- [Vemlidy (tenofovir alafenamide fumarate)](https://sec-api.dev/pdufa/tenofovir-alafenamide): 
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil): Ulcerative Colitis
- [TUB-040](https://sec-api.dev/pdufa/tub-040): NSCLC
- [YuTuo (zimberelimab)](https://sec-api.dev/pdufa/zimberelimab): Non-small Cell Lung Cancer
- [Zimberelimab (zim)](https://sec-api.dev/pdufa/zimberelimab-zim): Lung Cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/gild/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GILD catalysts: GILEAD SCIENCES, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/gild/catalysts

```bibtex
@misc{secapidev_companies_gild_catalysts_20261116,
  title        = {GILD catalysts: GILEAD SCIENCES, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/gild/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_gild_catalysts_20261116","title":"GILD catalysts: GILEAD SCIENCES, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/gild/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
